靶向表皮生长因子受体治疗肿瘤(3)
7.Fan,Z; Baselga,J; Masui,H. etc al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cel xenografts. Cancer Res; 53:4637-4642,1992.
8. Perrotte,P; Matsumoto,T;Inoue,K; etc al. Anti- epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res;5:257-265,1999.
, http://www.100md.com
9. Baselga,J; Pfister,D; Cooper,M.R; etc al. Phase 1 studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J.Clin.Oncol; 18:904-914,2000.
10. Hong, W. K; Arquette, M; Nabell, L; etc al. Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol; 21: 224, 2001.
, 百拇医药
11. Baselga, J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol; 11 (Suppl.13): 187-190,2000.
12. Kris,M.G; Herbst,R; Rischin,D; etc al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (‘Iressa’),a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29(Suppl. 1): 72,2000.
13. Ciardiello, F; Caputo,R; Bianco,R; etc al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin. Cancer Res; 6: 2053-2063,2000.
, http://www.100md.com
14. Sirotnak, F. M; Zakowsky, M. F; Mil1er, V. A; etc al. Efficacy of cytotoxic agents against human tumor xe- nografts is markedly enhanced by coadministration of ZDI839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res; 6: 4885-4892.2000.
15. Raben, D; Helfrich, B; Phistry, M;etc al.ZD1839 (Iressa), an EGFR-TKI potentiates radiation/chemotherapy cytotoxicity in human non-small ceIL lung cancer (NSCLC) cell lines.11th NCI-EORTC-AACR Symposium of New Drugs in Cancer Therapy, Abs. LB4,Amsterdam, November 7-IO, 2000.
, 百拇医药
16. Ciardiello,F; Caputo,R; Bianco, R; etc al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZDI839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res; 7: 1459-1465. 2001 .
17. TaMura,T; Nakagawa, K; Fukuoka, M; etc al. A Phase I intermittent dose-escalation trial of ZDI839 ('Iressa') in Japanese patients with solid malignant tumors. Lung Cancer. 29 (Suppl. 1): 71, 2000., http://www.100md.com(翁毅敏)
8. Perrotte,P; Matsumoto,T;Inoue,K; etc al. Anti- epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res;5:257-265,1999.
, http://www.100md.com
9. Baselga,J; Pfister,D; Cooper,M.R; etc al. Phase 1 studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J.Clin.Oncol; 18:904-914,2000.
10. Hong, W. K; Arquette, M; Nabell, L; etc al. Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol; 21: 224, 2001.
, 百拇医药
11. Baselga, J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol; 11 (Suppl.13): 187-190,2000.
12. Kris,M.G; Herbst,R; Rischin,D; etc al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (‘Iressa’),a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29(Suppl. 1): 72,2000.
13. Ciardiello, F; Caputo,R; Bianco,R; etc al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin. Cancer Res; 6: 2053-2063,2000.
, http://www.100md.com
14. Sirotnak, F. M; Zakowsky, M. F; Mil1er, V. A; etc al. Efficacy of cytotoxic agents against human tumor xe- nografts is markedly enhanced by coadministration of ZDI839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res; 6: 4885-4892.2000.
15. Raben, D; Helfrich, B; Phistry, M;etc al.ZD1839 (Iressa), an EGFR-TKI potentiates radiation/chemotherapy cytotoxicity in human non-small ceIL lung cancer (NSCLC) cell lines.11th NCI-EORTC-AACR Symposium of New Drugs in Cancer Therapy, Abs. LB4,Amsterdam, November 7-IO, 2000.
, 百拇医药
16. Ciardiello,F; Caputo,R; Bianco, R; etc al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZDI839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res; 7: 1459-1465. 2001 .
17. TaMura,T; Nakagawa, K; Fukuoka, M; etc al. A Phase I intermittent dose-escalation trial of ZDI839 ('Iressa') in Japanese patients with solid malignant tumors. Lung Cancer. 29 (Suppl. 1): 71, 2000., http://www.100md.com(翁毅敏)